Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) stock suffered a major decline of -12.1% on 3/11/24. The shares closed at $29.40. Moreover, trading volume in this decline was above average at 132% of normal. The stock has performed in line with the market over the last nine months and has declined -18.5% during the last week.
Current PriceTarget Research Rating
Reflecting future returns on capital that are forecasted to be in line with the cost of capital, ARWR is expected to continue to be Value Creation neutral.
Arrowhead Pharmaceuticals has a current Value Trend Rating of F (Lowest Rating). This rating combines inconsistent signals from two proprietary PTR measures of a stock’s attractiveness. Arrowhead Pharmaceuticals has a neutral Power Rating of 47 but a very low Appreciation Score of 3, with the Lowest Value Trend Rating the result.
Rating Review
In light of this highly negative price change we are reviewing our current Overall Rating of F. This review will be completed in the next several days.
Be the first to comment